Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for relapsed or therapy-resistant mantle cell lymphoma
2007-001108-19Phase 2Active
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in mantle cell lymphoma (MCL), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoints: Complete remission and partial remission rate and Safety and tolerability. Started Jun 2008; status: active.
02
Drugs
everolimus
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2007-001108-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001108-19.